19 results about "Pulmonary alveolus" patented technology

The application discloses a butyl tin-cycloiridium phenanthroline complex with an aggregation-induced emission (AIE) property, a preparation method of the complex and anticancer application of the complex. The structural formula of the complex is shown as formula (I), and R is one of hydrogen, a phenyl group, a p-tolyl group, a p-bromophenyl group, a p-fluorophenyl group, a biphenyl group, a triphenylamine group, a carbazole group, a tetraphenyl ethene group and a triphenylbenzene group. The growth inhibition rates of the target compound on human alveolar basal epithelial carcinoma cells (A549) and cisplatin-resistant cells (A549 / DDP), cervical cancer cells (Hela) and human lung normal epithelial cells (BEAS-2B) are tested, and it is found through comparison that the target compound shows potential anticancer activity. In addition, the target compound shows unique AIE emission characteristics. The target compound mainly targets the lysosomes of A549 cells, and influences the mitochondria to cause the decline of the mitochondrial membrane potential, thereby showing anticancer activity.

The present application relates to the technical field of medical information monitoring, and more particularly to a non-invasive carbon dioxide partial pressure monitoring ear clip and an intelligent monitoring method thereof, comprising: determining that a trigger alarm is determined based on a theoretical carbon dioxide partial pressure value to determine that the partial pressure is unqualified; determining the content unqualified based on the evaluation concentration value; determining the alarm state according to the relationship between the first deviation value and the risk deviation value; in response to determining that the content is unqualified, determining that the second evaluation is inaccurate based on the actual standard deviation value; according to the relationship that the second deviation value is less than or equal to the second deviation threshold, the evaluation concentration value is re-determined based on the theoretical carbon dioxide partial pressure value, so as to re-determine the partial pressure qualification, and the early warning concentration range is re-determined according to the second deviation value; the present application can quickly and accurately obtain the carbon dioxide partial pressure condition through multi-parameter coupling in a non-invasive manner, and can master the alveolar ventilation function and the respiratory function in real time through the carbon dioxide partial pressure condition.

According to some embodiments of the present invention, an artificial intelligence model-based classification device for the pulmonary fibrosis state of a stem cell-derived alveolar organoid comprises: a processor; and a memory configured to store instructions that cause the processor to perform operations when executed by the processor, wherein the operations include: an operation of extracting image features from a classification target image representing an alveolar organoid derived from a stem cell using a backbone network of an artificial intelligence neural network-based classification model, and an operation of classifying the state of the classification target image corresponding to the image features into a state of pulmonary fibrosis occurrence or a state of non-pulmonary fibrosis occurrence using a head network of the classification model, wherein the classification model is trained based on a training dataset, and the training dataset includes a first image dataset regarding an alveolar organoid in a first state in which pulmonary fibrosis has not occurred and a second image dataset regarding an alveolar organoid in a second state in which pulmonary fibrosis has occurred due to processing of a pulmonary fibrosis-inducing factor.

This invention discloses the application of lily-derived nanovesicles (LDPNVs) as a novel radiation protection drug in radiation-induced lung injury, relating to the field of biomedical technology. It includes administering effective doses of lily-derived nanovesicles to subjects to prevent and alleviate radiation-induced lung injury. The LDPNVs can improve the viability and clonal survival rate of radiation-damaged lung epithelial cells at the cellular level, and alleviate pathological damage to lung tissue and improve lung function at the animal level. This invention achieves the blocking of core pathways of radiation injury, specifically downregulating the expression of key inflammatory factors, reducing lactate dehydrogenase release and total protein content in bronchoalveolar lavage fluid, and correcting abnormal respiratory rate and ventilatory dysfunction. It yields a novel radiation protection drug for radiation-induced lung injury that is naturally derived, stable in preparation, highly targeted, and has a definite protective effect, filling the application gap of plant-derived nanovesicles in this field and providing a safe and effective intervention for complications of radiotherapy for thoracic tumors.

This invention provides a susceptibility gene for Th2-type asthma, a drug for it, and its application. The susceptibility gene is ALOX15, and the drug is an inhibitor of ALOX15 expression. This invention is the first to discover the relationship between ALOX15 and its main product, 15-HETE-PE, and Th2-type asthma. Inhibition of ALOX15 expression significantly reduces eosinophil expression and the number and percentage of eosinophils in blood and bronchoalveolar lavage fluid. Therefore, specific treatment targeting ALOX15 can serve as a novel treatment for asthma. The drug of this invention effectively reduces eosinophil count in animal and cell experiments, achieving a therapeutic effect for Th2-type asthma. This is a significant advantage compared to some refractory asthma patients whose eosinophil count cannot be reduced to normal levels with existing treatments.

The application belongs to the technical field of biological medicine, and discloses application of xanthine in repairing respiratory epithelial injury drugs and a chronic obstructive pulmonary disease (COPD) organoid model construction and evaluation method. In view of the defects that existing treatment focuses on inflammation control, relies on multi-drug combination, lacks epithelial repair targeting and has low pathological similarity in vitro model, an airway-alveolus organoid model is innovatively constructed, the pathological chain of COPD airway injury-alveolus destruction can be completely reproduced, and a multi-dimensional evaluation system is established. Based on the model, it is first proved that xanthine single drug can significantly promote proliferation of damaged airway organoid cells, inhibit abnormal apoptosis, selectively down-regulate release of inflammatory factors such as TNF-alpha and CXCL1, promote alveolus organoid AT2 cell proliferation and regeneration, and repair alveolus homeostasis at a concentration of 20-100 muM without combination with other drugs. Xanthine is an endogenous purine metabolite, is safe and low-toxic, solves the pain points of existing drug combination dependence and side effects, and realizes upgrading from inflammation control to structure repair. Xanthine can be made into oral or respiratory tract local preparations, is suitable for repairing epithelial injury of respiratory diseases such as COPD and asthma, is suitable for a wide range of people, has significant clinical and industrialization values, and the innovative model also provides a reliable tool for related drug research and development.

This invention discloses the application of Ganoderma lucidum extract rich in triterpenoid ganoderic acids in the preparation of drugs for treating chronic obstructive pulmonary disease (COPD). This invention is the first to systematically evaluate the repair effects of Ganoderma lucidum extract on COPD damage using airway and alveolar organoid platforms. Mouse and human COPD lung organoid experiments demonstrated that the triterpenoid-rich Ganoderma lucidum extract significantly promoted ciliated cell regeneration, inhibited mucus hypersecretion, maintained basal stem cell homeostasis, inhibited inflammatory factor release, promoted epithelial cell proliferation, inhibited apoptosis, and promoted the regeneration of alveolar type II epithelial cells (AT2) in an alveolar organoid model. In vivo COPD mouse models confirmed that Ganoderma lucidum extract significantly improved survival rate, protected alveolar structural integrity, and reduced airway inflammation. LC-MS / MS analysis showed that it mainly contains triterpenoid components such as ganoderic acids A, B, C₂, C₆, D, H, G, and ganoderic acid A, and exerts its protective effect by regulating the AKT and Wnt signaling pathways. This invention provides new candidate drugs for the treatment of COPD and lays a solid experimental foundation for the development of lung injury repair drugs with independent intellectual property rights, showing broad prospects for clinical translation and industrial application.

This invention proposes a method for isocarbonyl hyperventilation to protect alveolar epithelial cells from oxidative damage. It belongs to the field of medical respiratory therapy technology. The method includes: providing patients requiring respiratory support with a minute ventilation volume higher than physiologically required, while simultaneously supplementing the inhaled air with exogenous carbon dioxide using a gas mixing device; continuously monitoring the patient's end-tidal carbon dioxide partial pressure, the concentration of 8-isoprostaglandin in exhaled condensate, and pH value, among other oxidative stress biomarkers, using monitoring equipment; and precisely regulating gas composition and ventilation parameters through isocarbonyl hyperventilation to create a suitable microenvironment for alveolar epithelial cells, effectively neutralizing excessive intracellular oxidative substances, reducing direct damage to cells from oxidative stress, and decreasing adverse effects such as cell membrane lipid peroxidation and protein denaturation, thereby significantly improving the survival rate and normal function maintenance capacity of alveolar epithelial cells.

This invention discloses a method for determining the lung recruitment endpoint using the PARDS ultrasound regasification score in children, relating to the field of pediatric critical respiratory support therapy. It solves the technical problem of existing technologies being unable to perform real-time dynamic zonal assessment of alveolar recruitment status in different lung regions, especially gravity-dependent areas, which easily leads to inadequate lung recruitment treatment. This invention performs standardized zonal ultrasound examination of the child's lungs during lung recruitment, employing a graded and quantified ultrasound regasification scoring system to assign values ​​to the lung ventilation level of each examined region. The total ultrasound regasification score is calculated by summing these values. With the core condition of continuously increasing PEEP and no further increase in the total score after plateau pressure, this invention can achieve objective and accurate determination of the lung recruitment endpoint, ensuring the adequacy and safety of lung recruitment treatment. It is applicable to the management of mechanical ventilation in children with acute respiratory distress syndrome.

The present invention provides a method and composition for use in growing alveolar epithelial cells.The method can include the use of a three-dimensional substrate and an improved technique for growing cells.The improved composition for culturing alveolar epithelial cells can include at least one or more of the following: a TGF-β pathway inhibitor, a Wnt pathway activator, a ROCK inhibitor, epidermal growth factor (EGF), keratinocyte growth factor (KGF), and fetal bovine serum.

This invention discloses a non-invasive positive pressure ventilation device for small animals, comprising a positive pressure breathing chamber, an animal restraint, and a positive pressure ventilator. The animal restraint includes an animal restraint bottle and a neck sealing strap, with the animal restraint bottle placed inside the positive pressure breathing chamber. The neck sealing strap is fixed to one side of the opening of the animal restraint bottle. The positive pressure ventilator is connected to the positive pressure breathing chamber. This invention achieves non-invasive positive pressure ventilation: it can explore the effects of non-invasive positive pressure ventilation on the structure and function of the airway and lungs in animals, and can well simulate the changes in airway and alveolar structure, function, and various mechanisms during long-term use of a non-invasive ventilator in patients with chronic respiratory failure. Furthermore, it achieves long-term positive pressure ventilation: it enables animals to receive positive pressure ventilation for extended periods, allowing them to receive several hours of positive pressure ventilation daily and achieve spontaneous breathing for several hours each day, accurately simulating an animal model of long-term non-invasive positive pressure ventilation in patients with chronic obstructive pulmonary disease and chronic respiratory failure.

A novel strain, Lactobacillus paracasei ATG-E1 (Accession No. KCTC 14245BP), and a composition containing the same for preventing or treating respiratory diseases which are caused by fine particulate matter. The Lactobacillus paracasei ATG-E1 strain reduces the number of immune cells bronchoalveolar and lung tissues and inhibits the expression of inflammatory cytokines such as interleukin-17A (IL-17A), tumor necrosis factor-α (TNF-α), macrophage inflammatory protein 2 (MIP2), C-X-C motif chemokine ligand 1 (CXCL-1), macrophage inflammatory protein-α (MIP-1α) or interleukin-6 (IL-6). Therefore, the Lactobacillus paracasei ATG-E1 strain can be used for a treatment or health functional food for various respiratory diseases such as acute and chronic bronchitis, catarrhal bronchitis, bronchitis obliterans, inflammatory bronchitis, bronchial asthma, atopic asthma, non-atopic asthma, atopic IgE-mediated asthma, allergic asthma, non-allergic asthma, chronic bronchoconstriction, acute bronchoconstriction, chronic obstructive pulmonary disease, bronchial adenoma, pulmonary tuberculosis, emphysema, lung abscess, pulmonary fibrosis, lung cancer, airway cancer, bronchoalveolar cancer, and bronchial cancer.

This invention relates to the field of traditional Chinese medicine (TCM) technology, and particularly to the application of TCM compositions in the preparation of drugs for the prevention and treatment of asthma. The TCM composition includes Astragalus membranaceus, Eupolyphaga sinensis, Morus alba root bark, Fritillaria cirrhosa, Perilla frutescens seed, Lepidium apetalum seed, Prunus armeniaca seed, Pheretima aspergillum, Ephedra sinica, and Clematis chinensis. Experiments show that the TCM composition provided by this invention can effectively improve airway hyperresponsiveness, reduce lung resistance, and enhance dynamic lung compliance in asthma model animals. Simultaneously, it can significantly reduce the content of pro-inflammatory factors IL-4 and IL-13 in the bronchoalveolar lavage fluid of asthma models, alleviate airway inflammation, and relieve asthma pathological symptoms. It can stably exert its effect in preventing and treating asthma, and its efficacy is stable and its safety is good. It can be further developed into a drug for the prevention and treatment of asthma and has good clinical application prospects.

A traditional Chinese medicine composition for improving or treating acute lung injury and an application thereof. The traditional Chinese medicine composition is made of the following traditional Chinese medicine raw materials: Areca catechu 12-24 parts, Magnolia officinalis 6-12 parts, Amomum tsao-ko 3-6 parts, Anemarrhena asphodeloides 6-12 parts, Paeonia lactiflora 6-12 parts, Scutellaria baicalensis 6-12 parts, Glycyrrhiza uralensis 3-6 parts, Rheum officinale 6-12 parts, Forsythia suspensa 8-16 parts, Mentha haplocalyx 3-6 parts, Gardenia jasminoides 3-6 parts, Mirabilite 3-6 parts, and Bambusa 5-10 parts. In a mouse animal model experiment, the traditional Chinese medicine composition described herein not only can alleviate the phenomenon of inflammatory cell infiltration in the bronchoalveolar lavage fluid caused by LPS, reduce the inflammatory response, but also can help to improve the lung tissue pathological injury induced by LPS, maintain the alveolar structure integrity, inhibit pulmonary edema, down-regulate the level of inflammatory factors in the bronchoalveolar lavage fluid, and inhibit the expression of inflammatory factors in the lung tissue, thereby improving or treating acute lung injury caused by LPS.

This invention discloses an intelligent assessment and rehabilitation guidance system for postoperative respiratory function in thoracic surgery, belonging to the field of intelligent medical rehabilitation systems. The invention collects postoperative time-dimensional data, recovery progress data, and real-time respiratory data from patients in real time through a data acquisition module. Based on this data, a dynamic prediction model module is used to construct a prediction model that can predict the trend of changes in the patient's respiratory function 3-7 days in advance. This ability to predict in advance allows medical staff to intervene promptly, adjust rehabilitation plans, and effectively prevent the occurrence of potential respiratory dysfunction, thereby promoting rapid patient recovery. For example, the system can identify the risk of alveolar hypoventilation or airway spasm in advance and automatically generate a proactive rehabilitation adjustment plan to ensure that patients receive timely and accurate treatment.

The application provides a method for calculating respiratory airflow and particle transport based on a dynamic coupling full airway model. The method comprises: constructing a five-branch full airway three-dimensional model comprising an upper airway segment, a triple bifurcation unit (TBU) segment, and an alveolar segment; establishing a dynamic motion model of the glottis, trachea, and alveolar region to realize the geometric change of the airway structure in the respiratory cycle; adopting a segmented independent simulation and step-by-step boundary condition transmission strategy to complete the transient airflow simulation in each level of the airway; and introducing a particle tracking mechanism to realize the simulation of the transport, deposition, and exhalation process of inhaled particles from the oral cavity to the alveoli. The above method combines real anatomical structure, dynamic physiological motion, and efficient calculation strategy to improve the accuracy and calculation efficiency of airflow and particle transport simulation, and is suitable for scenarios such as inhaled drug delivery, air pollution exposure assessment, and respiratory system disease modeling.

This invention belongs to the field of environmental and human health technology, and discloses a PM... 2.5 An alveolar microresponsive system carrying insoluble particles and a model for evaluating its relative bioefficacy. This alveolar microresponsive system establishes an alveolar microresponsive system by carrying insoluble PM... 2.5 A model for the bioaccumulation and relative bioavailability of -M, derived from lung surfactant extraction and PM2.5. 2.5 The process of incubating and extracting adsorbed substances from M, screening adsorbent layer lipids and proteomes, and assembling microreaction system models revealed the properties of water-insoluble PM. 2.5 The accumulation and absorption characteristics of PM2.5 particles in the alveoli; lipidomics and proteomics analyses clarified the composition of insoluble PM2.5 particles in the alveoli. 2.5 A degradation and transformation microreaction system consisting of -M and alveolar fluid was constructed, and a non-water-soluble PM2.5 was first constructed based on the microreaction system. 2.5 - Model for calculating alveolar turnover rate after M respiratory exposure and the amount of water-insoluble PM in alveoli 2.5 -M bioefficacy assessment model.

The present application relates to the technical field of pneumonia, and discloses a treatment method for pneumonia, S1: preliminary evaluation and diagnosis: S1.1: check symptoms (such as cough, fever, dyspnea, etc.); S1.2: physical examination, auscultation of the chest; S1.3: chest X-ray examination or CT scan to observe the lung image; S2: determine the specific pathogen through genome sequencing: S2.1: sample collection: first collect clinical samples from the patient, such as blood, sputum or bronchoalveolar lavage fluid; S2.2: DNA / RNA extraction: extract the genetic material of microorganisms from the sample, whether it is DNA or RNA, depending on the type of pathogen. The treatment method for pneumonia can accurately determine the type of pathogen causing pneumonia and its drug resistance, which helps to implement a more personalized and precise treatment plan. This not only can improve the success rate of treatment and reduce unnecessary broad-spectrum antibiotic use, but also helps to slow down the growth rate of antibiotic resistance.